Introduction
============

Lung cancer is one of the most common malignancies and the leading cause of cancer death worldwide with over one million deaths annually [@B1], [@B2]. Tobacco smoking confers 90% lung cancer cases, whereas inherited genetic factors also play an important role in individual predisposition to lung cancer [@B3]. Genome-wide association studies (GWAS) have significantly improved our understanding of inherited susceptibility to lung cancer [@B4]-[@B7].

According to Amos CI\'s paper, GWAS has found 45 lung cancer susceptibility loci [@B8]. Among them, chromosome 3q28 was first reported by Miki *et al*. in Japanese and Korean descent and two common variants rs10937405 and rs4488809 at 3q28 were identified associated with lung cancer risk [@B9]. This association was further replicated by our previous study in Chinese and European populations, respectively [@B5], [@B10], [@B11]. Genetic variants within this region were also associated with lung cancer risk, especially with adenocarcinoma in non-smoking Asian women [@B9], [@B12]. However, most of these variants reported by GWAS are merely the associated markers and the underlying molecular bases of these associations are unknown. Fine mapping is useful to survey the possible variants for further follow-up studies to understand the biological basis [@B13]-[@B15].

In the past several years, fine mapping studies of lung cancer have been performed in 15q25, 5p15.33 and major histocompatibility complex (MHC) regions, while the chromosome 3q28 remains unclear [@B16]-[@B19]. Therefore, to localize the potentially causal variants at 3q28 associated with lung cancer susceptibility, we conducted a two-stage fine-mapping study, which consisted of a target region resequencing on 200 lung cancer cases and 300 controls (Discovery cohort) and an association analysis in silico with 12,843 lung cancer cases and 12,639 controls (Validation cohort). The Expression quantitative trait loci (eQTL) analysis and gene differential expression analysis were further applied to explore the possible target genes through which genetic variants in 3q28 modified lung cancer susceptibility. This study would provide us a deeper insight into the genetic mechanisms of variants in 3q28 in the development of lung cancer.

Materials and Methods
=====================

Study subjects
--------------

### Discovery cohort

Two hundred newly diagnosed lung cancer patients and 300 age-matched and sex-matched controls were involved in the study. These individuals were also a proportion of our previous GWAS subjects [@B5], [@B20]. Lung cancer cases were recruited from the Cancer Hospital of Jiangsu Province and the First Affiliated Hospital of Nanjing Medical University since 2003. Patients were confirmed non-small cell lung cancer (NSCLC) without radiation, chemotherapy or had a history of cancer, metastasized cancer from other organs. Controls were selected from individuals participating in a community-based screening program for non-infectious diseases conducted in Jiangsu province during the same period when the cases were recruited. The controls were frequency matched to the cases on age (±5 years) and gender.

All of the participants were genetically unrelated ethnic Han Chinese individuals, and they each donated approximately 5-ml of venous blood. Smoking information were collected through face-to-face interviewed by trained interviewers and those who had smoked less than an average of one cigarette per day and \< 1 year in their lifetime were defined as nonsmokers; while others were considered as smokers. This study was conducted with approval of the institutional review board of Nanjing Medical University and informed consent was obtained from all participants.

### Validation cohort

The validation cohort included our previous GWAS subjects (NJMU GWAS), consisting of 2,331 lung cancer cases and 3,077 controls form Nanjing and Beijing; and additional 10,512 lung cancer cases and 9,562 controls from the Female Lung Cancer Consortium in Asia (FLCCA) [@B21] and the National Cancer Institute (NCI) GWASs which were obtained via the database of Genotypes and Phenotypes (dbGAP) [@B22]. The FLCCA (dbGaP Study Accession: phs000716.v1.p1) investigated the etiology of lung cancer among never-smoking women in Asia, including 5,510 lung cancer cases and 4,544 controls from 14 studies from mainland China, South Korea, Japan, Singapore, Taiwan and Hong Kong [@B23] ( <http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000716.v1.p1>). Among these subjects, 4,922 lung cancer cases and 3,959 controls are available in dbGAP. The NCI GWASs (dbGaP Study Accession: phs000336.v1.p1) were derived from one population-based case-control study and three cohort studies specifically: the Environment and Genetics in Lung Cancer Etiology (EAGLE) (dbGaP Study Accession: phs000093.v2.p2), the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), the Prostate, Lung, Colon, Ovary Screening Trial (PLCO) and the Cancer Prevention Study II Nutrition Cohort (CPS-II) (<http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000336.v1.p1>). The four studies (EAGLE, ATBC, CPS-II and PLCO) were divided into two data sets because the EAGLE study provided the smoking information and the others didn\'t offer. We obtained EAGLE study data from dbGaP phs000093.v2.p2, which included 1,945 cases and 1,992 controls (SLD) in Italy between 2002 and 2005. The other three studies included 3,782 cases and 3,840 controls (CADM, dbGap phs000336.v1.p1). Among these three studies, ATBC is a randomized primary prevention trial in Finland between 1985 and 1993. Both PLCO and CPS-II were conducted in U.S. states. The population characteristics of these studies were shown in **Table [S1](#SM0){ref-type="supplementary-material"}**.

Quality control and imputation of GWAS data sets
------------------------------------------------

The NJMU GWAS was conducted using Affymetrix Genome-Wide Human SNP Array 6.0 with standard quality control procedures conducted in previous study [@B5], [@B20]. Though the data sets from the dbGaP were described to be deposited after the initial quality control, we performed standard quality control on these data sets. We eliminated individuals with low call rates (95%), familial relationships and extreme heterozygosity rates, and excluded SNPs with low call rates (95%), MAF (minor allele frequency) \< 0.05 and *P* \< 1×10^-6^ for the Hardy-Weinberg equilibrium (HWE). After quality control, 4,796 cases and 3,741 controls from FLCCA, 1,937 cases and 1,984 controls from SLD, and 3,779 cases and 3,837 controls from CADM remained. The genotyping data were imputed using the 1000 Genomes Project data (the Phase III integrated variant set release, across 2,504 samples) as a reference. We then phased the haplotypes with Shapeit v2 (<http://www.shapeit.fr/>, Phasing step) and imputed with IMPUTE2 (<http://mathgen.stats.ox.ac.uk/impute/impute_v2.html>). Poorly imputed SNPs defined by an information measure \< 0.40 with IMPUTE2 were further excluded from the analysis.

Target region sequencing and genotyping
---------------------------------------

We used the HapMap Project database (phase II + III Feb 09, on NCBI B36 assembly, dbSNP126), to explore the LD structure around the SNP rs4488809, as previously reported by Miki *et al.* [@B9]. Finally, an LD block spanning from chr3: 189214000 to chr3: 189428000 (hg19) was included in our study. In total, 248 probes (total size: 131.73 kb; coverage: 61.56%) were designed using Agilent Sure Select software (<http://earray.chem.agilent.com/eArray>) and captured through Agilent Sure Select protocol (Agilent Technologies, Santa Clara, California, USA). The following sequencing experiment was performed on a Genome Analyzer IIx (Illumina, San Diego, CA) [@B24]. Sequencing adapters and low-quality reads were filtered using the FASTQ Quality Filter tool. The high-quality reads were aligned to the human genome reference sequence (hg19) using Burrows-Wheeler Aligner (BWA, V.0.5.9) (<http://bio-bwa.source-forge.net>) [@B25]. Duplicates were marked using Picard Tools (<http://picard.sourceforge.net/>), and the base quality scores were recalibrated using Genome Analysis Toolkit (GATK, V.1.0.5974). Variants were called by GATK and Freebayes, and only those variants identified by both tools were taken into account.

We ruled out 8 lung cancer cases and 22 control subjects because they (i) had a low consistent rate (\< 90%) as determined by comparing overlapped single nucleotide variants (SNVs) against existing NJMU GWAS data or (ii) yielded a read depth \< 10× across samples. A total of 1,515 variants were detected through targeted resequencing. Among them, 1107 variants were excluded from subsequent analyses for the following reasons: (i) call rate of genotype \< 90%; (ii) *P* value for HWE \< 1×10 ^-4^ in case, control or all subjects; (iii) MAF \< 0.05 (control); (iv) concordance rate \< 90% with the previous GWAS for overlapping variants if applied; or (v) not in the 1000 Genomes Project ([www.1000genomes.org](http://www.1000genomes.org)) (QC details in **Figure [1](#F1){ref-type="fig"}**). Finally, 408 common SNVs in 192 cases and 278 controls were retained for subsequent association analysis. Gemini (V.0.18.3) and snpEff (V.3_6) were used to annotate the function of the genetic variants from the targeted resequencing. The associations between each variant and lung cancer risk in the discovery cohort were calculated using logistic regression model with adjustment for age, sex and smoking statue in PLINK (V.1.90). Conditional analysis was performed using an approximated joint regression model in GCTA [@B26] to select index variants in 3q28 region, and those with nominal evidence of association (*P* \< 0.05) were selected for further validation in multiple GWAS data sets.

Validation of identified SNVs
-----------------------------

We validated the SNVs identified in targeted resequencing using multiple lung cancer GWASs in both Asian and European populations. Association analysis was performed using SNPTEST v2.5 under a probabilistic dosage model with adjustment for age, sex, smoking pack-year and the first principal component (PCA) in NJMU GWAS, age in FLCCA GWAS, age, sex, smoking status and the first PCA in SLD GWAS, and age, sex and the first PCA in CADM GWASs. The effect estimates and *P* values of candidate SNVs in each GWAS data set were then combined using SNPTEST separately by Asian and European populations. Finally, fixed-effect meta-analysis was conducted to assess pooled genetic effects in the validation stage. The Cochran\'s Q statistic and*I*^2^ were calculated using STATA software (V.8.0, College Station, TX, USA) to test the heterogeneity between studies. General analyses were performed with R software (version 3.1.1; The R Foundation for Statistical Computing).

Functional element analysis and gene expression analysis
--------------------------------------------------------

These novel SNPs were investigated for the presence of chromatin histone marks and hypersensitive DNAse elements using data from ENCODE included in HaploReg v4.1 (<http://www.broadinstitute.org/mammals/haploreg/haploreg.php>) and the UCSC genome browser (<https://genome.ucsc.edu/cgi-bin/hgGateway>). The results and boxplots of the eQTL analysis in the lung tissue (383 samples) from the Genotype-Tissue Expression (GTEx) project were obtained from the version of GTEx Portal.v7 (<http://www.gtexportal.org/>).

Results
=======

Characteristics of study subjects
---------------------------------

In the current study, 192 lung cancer cases and 278 controls were finally included in the discovery cohort after quality control. Among the cases, 63 samples were squamous cell carcinoma (SCC) and 129 cases belonged to lung adenocarcinoma (AD). Male individuals accounted for more than 70% of subjects in discovery cohort. The distributions of gender and age were similar in cases and controls. Notably, cases had a higher proportion of smoking than that in controls (67.2% vs 47.5%). Characteristics of subjects in validation cohort had been described in our previous studies. The detailed information of study subjects in discovery and validation cohorts was summarized in **Table [S1](#SM0){ref-type="supplementary-material"}**.

Association results in discovery cohort
---------------------------------------

Of the 408 variants that were analyzed, 34 were significantly associated with lung cancer risk at *P* values less than 0.05, including three genetic variants which were identified by previous GWASs (rs4488809, rs10937405 and rs13314271) (**Table [S2](#SM0){ref-type="supplementary-material"}**). The directions of effects between the three SNPs and lung cancer risk were consistent with previous reports, and effect sizes were similar. Through approximate conditional analysis with GCTA, we identified six novel SNPs significantly associated with lung cancer risk (**Table [1](#T1){ref-type="table"}**): rs17443378 (OR = 1.96, *P* = 0.026), rs3856776 (OR = 2.05, *P* = 1.49×10^-3^), rs4396880 (OR = 0.35, *P* = 3.01×10^-4^), rs4687064 (OR = 1.69, *P* = 0.034), rs57830317 (OR = 2.55, *P* = 2.76×10^-4^) and rs6798700 (OR = 0.29, *P* = 3.08×10^-5^).

Validation in lung cancer GWASs and evaluation for independence
---------------------------------------------------------------

To validate the SNVs identified by targeted resequencing, we performed association analysis in multiple lung cancer GWASs divided by Asian and European populations (**Table [1](#T1){ref-type="table"}**). Although no SNVs reached a genome-wide significance level of association (*P* \< 5.0 × 10^-8^), two of the six SNVs showed a consistent association with lung cancer risk in Asian population. They are rs3856776 (OR = 1.17, 95% CI: 1.08-1.27,*P* = 1.64 × 10^-4^), and rs4396880 (OR = 0.88, 95% CI: 0.84-0.93,*P* = 7.43 × 10^-6^). However, no associations were observed for the two SNPs in European population. Based on LD analysis (**Figure [2](#F2){ref-type="fig"}**), rs4396880 was in LD with previous reported risk variants rs4488809, rs10937405 and rs13314271 (*r*^2^ = 0.44 to 0.95), while rs3856776 could not been tagged by these variants (*r*^2^ \< 0.05). We applied conditional analysis to test the independence of rs4396880 and rs3856776 and used the predefined variants as covariates. Interestingly, after conditioning on the previously reported SNVs in this region, denoted by rs4488809 and rs10937405, only the association observed for rs4396880 was largely attenuated (*P~\_~*~Conditional~=0.136 for rs4396880), while the association for rs3856776 remained essentially unchanged (**Table [2](#T2){ref-type="table"}**). Furthermore, after conditioning on rs4396880 and rs3856776, the GWAS SNVs were no longer significant in the targeted resequencing analysis (all *P~\_~*~Conditional~ \> 0.05, **Table [S3](#SM0){ref-type="supplementary-material"}**). We then performed stratification analysis of the two identified variants by age, gender, smoking status and histology and did not find significant effect difference between subgroups (**Table [3](#T3){ref-type="table"}**).

Functional evaluation
---------------------

To explore the potential mechanism of the associations, we annotated the two newly identified variants using public databases (ENCODE and Roadmap Epigenomics Project database). We found that rs4396880 was located in DNase I hypersensitivity site (DHS) and regulatory histone modification signals in multiple cell types**.** Further eQTL annotation with GTEx v7 database suggested that the A allele of rs4396880 was associated with the increased mRNA expression of *TP63* in 383 normal lung tissues (β = 0.19, *P* = 1.70×10^-4^, **Figure [3](#F3){ref-type="fig"}A**). Besides, we also found that rs4396880 showed significant association with tumor protein p63 regulated 1 (*TPRG1*) expression (β = 0.093, *P* = 0.013, **Figure [3](#F3){ref-type="fig"}B**). *TP63* was aberrantly upregulated in lung tumor tissues based on TCGA database (*P* = 3.00×10^-7^, **Figure [4](#F4){ref-type="fig"}A**), while the expression of *TPRG1* was significantly decreased in tumor tissues (*P* = 1.81×10^-6^, **Figure [4](#F4){ref-type="fig"}B**). For rs3856776, genotypes of this variant showed no significant association with *TP63* (β = -0.03, *P* = 0.550, **Figure [3](#F3){ref-type="fig"}C**). Notably, SNP rs3856776 was associated with the expression of antisense *LEPREL1-AS1* (β = 0.13, *P* = 6.90×10^-3^, **Figure [3](#F3){ref-type="fig"}D**). Interestingly, *LEPREL1* expression was aberrantly downregulated in lung tumor tissues (*P* = 2.54×10^-18^, **Figure [4](#F4){ref-type="fig"}C**).

Discussion
==========

In this study, we provided a relatively comprehensive genetic landscape at 3q28 in Chinese subjects by sequencing \~214 kb on *TP63* region. We newly identified two genetic variants (rs4396880 and rs3856776) that were associated with lung cancer risk and subsequently validated in large-scale GWASs within Asian population. What\'s more, rs3856776 was a novel independent lung cancer susceptibility variant.

The *TP63* gene whose product is the tumor protein P63, transcriptionally regulates genes involved in DNA repair [@B27], [@B28] and is important for normal development and differentiation of stratified epithelial tissues as well as for human carcinogenesis [@B29], [@B30]. In addition, p63 has been found to play an important role in cell cycle arrest and apoptosis through its interaction with mutant p53 [@B31], [@B32]. Altered*TP63* expression has been linked to the development and progression of various types of cancers, including lung cancer [@B31], [@B33]. The most commonly reported variant variants in the *TP63* gene, rs4488809 and rs10937405, were first identified in lung cancer GWAS in Asia [@B9], and consistently replicated in other Asian populations [@B5] and Europeans [@B34]. In our study, the variant rs4396880 was 40bp away from rs4488809 (*r*^2^ = 0.46, D\' = 1.00) and 27kb from rs10937405 (*r*^2^ = 0.95, D\' = 0.98). These three SNPs were included in the *TP63* isoforms of TAp63 that are transcribed using a promoter upstream of exon 1, but not in other isoforms (△Np63) that are regulated by another promoter in intron 3 [@B35]. Interestingly, certain biologic hypotheses based on ENCODE are consistent with our statistical evidence. Rs4396880 demonstrates evidence of the DNase I hypersensitivity site (DHS) and histone modification marks H3K27Ac, H3K36M3 and H3K27Me3 consistent with promoter and enhancer activity in several cell lines, suggesting that it may have a functional role in the regulation of *TP63* gene expression. Notably, SNP rs4396880 was also associated with the expression of *TPRG1*, which was significantly downregulated in lung tumor tissues. However, limited study was available about the function of *TPRG1*. Highlighting these findings, we speculate that rs4396880 A allele may modulate lung cancer risk by increased mRNA expression of *TP63*.

In the current study, we also identified an intergenic variant rs3856776 in 3q28 (50kb upstream of *TP63*) that was independently associated with lung cancer risk. The variant was not in LD with the previously reported variants. Interestingly, SNP rs3856776 was not associated with the expression of *TP63*, suggesting that this variant could modulate lung cancer susceptibility through other mechanisms. Importantly, a significant association between rs3856776 and antisense RNA *LEPREL1-AS1* expression was observed according to GTEx database. *LEPREL1* (leprecan-like 1, also known as *P3H2*) encodes a member of the P3H2 dioxygenases and participates in the collagen chain assembly, stability and cross-linking [@B36], [@B37]. Mutation in*LEPREL1* had been reported associated with the risk of myopia [@B38], [@B39]. Previous studies indicated that*LEPREL1* was significantly downregulated in breast cancer, lymphoma and hepatocellular carcinoma tissues and could function as a tumor suppressor [@B40]-[@B42]. Notably, in this study, we found that the expression of*LEPREL1* was also aberrantly decreased in lung tumor tissues, suggesting that *LEPREL1* might also play a tumor suppressor role in lung cancer. The antisense RNA of *LEPREL1* (*LEPREL1-AS1*) could suppress the translation of *LEPREL1*. Taken together, rs3856776 might contribute to lung cancer risk by regulating the expression of *LEPREL1-AS1* through suppressing the translation of tumor suppressor gene*LEPREL1*.

In summary, we performed the first fine mapping studying focusing on 3q28 region, two variants were identified significantly associated with lung cancer risk in Asian population. What\'s more, rs3856776 was a novel independent lung cancer risk variant and might influence lung cancer susceptibility through suppressing the function of *LEPREL1*. However, this study also had some limitations. First, we only analyzed the common variants, rare variants were excluded because of the limited sample size in discovery cohort. Second, for our identified variants, we speculated their potential target genes and possible mechanisms through bioinformatics methods, functional studies are needed to validate our findings.
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![**LD plot of the two SNPs (rs4396880 and rs3856776) and other significant SNPs identified in previous studies.** LD between the newly found two distinct signals (rs3856776 and rs4396880) and the three previously reported SNPs at this locus are based on our data. The 2 SNPs associated with lung cancer susceptibility in this article are marked with red lines and the 3 SNPs identified previously are marked with green lines.](jcav10p1862g002){#F2}

![**The eQTL analysis of rs4396880 and rs3856776 in 383 normal lung tissues based on GTEx database.** Rs4396880 was significantly associated with *TP63* (**A**) and *TPRG1* expression (**B**); Rs3856776 showed no significant association with the expression of *TP63* (**C**), but was significantly associated with *LEPREL1-AS1* expression (**D**).](jcav10p1862g003){#F3}

![**Expression of *TP63*, *TPRG1* and *LEPREL1* in lung tumor tissues and adjacent normal tissues based on TCGA database.** *TP63* was aberrantly upregulated in tumor tissues (**A**); The expression of *TPRG1* was significantly decreased in tumor tissues (**B**); *LEPREL1* expression in tumor tissues was significantly downregulated compared with that in adjacent normal tissues (**C**).](jcav10p1862g004){#F4}

###### 

Multiple distinct signals of association with lung cancer risk at the *TP63* in the discovery and validation stages.

  SNP             Ref/Effect Allele   Discovery   Validation                                                                                                                             
  --------------- ------------------- ----------- ------------ ----------------- ------------- ----------------- ------------- ----------------- ------- ----------------- ------------- -------
  rs17443378      C/G                 0.28        0.32         1.96(1.08-3.54)   0.026         0.90(0.85-0.95)   1.10×10^-4^   0.98(0.93-1.03)   0.432   0.94(0.91-0.98)   2.00×10^-3^   0.027
  **rs3856776**   C/T                 0.13        0.08         2.05(1.32-3.18)   1.49×10^-3^   1.17(1.08-1.27)   1.64×10^-4^   1.01(0.96-1.07)   0.701   1.06(1.01-1.11)   0.016         0.003
  **rs4396880**   G/A                 0.26        0.35         0.35(0.20-0.62)   3.01×10^-4^   0.88(0.84-0.93)   7.43×10^-6^   0.98(0.92-1.03)   0.425   0.92(0.89-0.96)   3.68×10^-5^   0.006
  rs4687064       T/A                 0.22        0.18         1.69(1.04-2.76)   0.034         0.89(0.84-0.94)   5.66×10^-5^   0.95(0.88-1.03)   0.202   0.91(0.87-0.95)   5.19×10^-5^   0.186
  rs57830317      A/C                 0.29        0.22         2.55(1.54-4.23)   2.76×10^-4^   0.95(0.90-1.01)   0.086         1.00(0.95-1.06)   0.918   0.98(0.94-1.02)   0.230         0.206
  rs6798700       G/A                 0.27        0.26         0.29(0.16-0.51)   3.08×10^-5^   0.94(0.89-0.99)   0.027         1.02(0.97-1.08)   0.480   0.98(0.94-1.02)   0.267         0.034

^a^ EAF, effect allele frequency; ^b^ Derived from the GCTA joint regression model with adjustment for age, sex and smoking status; ^c^ Derived from the fixed effect meta-analysis of NJMU and FLCCA GWASs; ^d^ Derived from the fixed effect meta-analysis of the NCI studies (the EAGLE, ATBC, CPSII and PLCO studies). ^e^ Derived from the fixed-effect meta-analysis of the NJMU, FLCCA, EAGLE, ATBC, CPSII and PLCO studies.

###### 

Independent effect analysis by conditioning on rs4488809 and rs10937405.

  SNP         Ref/Eff Allele   MAF    Step 1   Step 2                                            
  ----------- ---------------- ------ -------- ----------------- ------------- ----------------- -------------
  rs4396880   G/A              0.26   0.35     0.64(0.47-0.87)   3.88×10^-3^   0.33(0.08-1.41)   0.136
  rs3856776   C/T              0.13   0.08     1.84(1.19-2.85)   6.05×10^-3^   1.80(1.15-2.81)   9.93×10^-3^

^a^ adjusted for age, sex and smoking status. ^b^ adjusted for age, sex, smoking status, rs4488809 and rs10937405.

###### 

Stratification analysis of the associations of rs3856776 and rs4396880 with lung cancer risk.

  Characteristics   rs3856776              rs4396880                                                                                            
  ----------------- ----------- ---------- ----------------- ------- ------- --------- ------------ ----------------- ----------------- ------- -------
  Age                                                                                                                                           
  \<60              82/16/4     123/21/0   1.65(0.90-3.01)   0.104   0.626             52/45/5      62/67/15          0.73(0.48-1.11)   0.144   0.404
  ≥60               67/19/4     113/21/0   2.06(1.07-3.98)   0.030           54/29/7   56/59/19     0.56(0.35-0.88)   0.012                     
  Sex                                                                                                                                           
  Male              109/24/7    165/33/0   1.68(1.02-2.79)   0.043   0.511             76/55/9      77/95/26          0.59(0.41-0.85)   0.004   0.454
  Female            40/11/1     71/9/0     2.38(0.96-5.90)   0.062           30/19/3   41/31/8      0.76(0.44-1.33)   0.344                     
  Smoke                                                                                                                                         
  Never             48/13/2     125/21/0   2.24(1.09-4.61)   0.029   0.493             37/23/3      67/57/22          0.64(0.39-1.03)   0.066   1
  Ever              101/22/6    111/21/0   1.63(0.94-2.84)   0.081           69/51/9   51/69/12     0.64(0.43-0.95)   0.028                     
  Histology ^d^                                                                                                                                 
  SCC               49/10/4     236/42/0   1.73(0.91-3.29)   0.091   0.871             33/24/6      118/126/34        0.72(0.44-1.15)   0.177   0.549
  AD                100/25/4    236/42/0   1.85(1.13-3.04)   0.014           73/50/6   118/126/34   0.60(0.42-0.85)   0.004                     

^a^ Sample size of subjects with wild type homozygote/heterozygote/variant homozygote; ^b^ Adjusted for age, sex and smoking status where is appropriate; ^c^ *P* for heterogeneity; ^d^ SCC, squamous cell carcinoma; AD, adenocarcinoma.
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